Gala Early Feasibility Study of RheOx

Chronic Bronchitis Clinical Trial

— Gala_EFS  

Official title:

A Feasibility Study: A Safety Evaluation of RheOx on Patients With Chronic Bronchitis in the United States

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03631472
• Other study ID #: CS003
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 6, 2018
• Est. completion date: December 30, 2024

Study information

• Verified date: April 2022
• Source: Gala Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An early feasibility study (EFS) to assess the safety and clinical utility of RheOx on patients with chronic bronchitis in the United States.

Description:

RheOx is a device-based, energy delivery system that delivers energy for the ablation of soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Two sessions of treatment will be delivered one month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session (approximately one month after the right side is treated). Treatment will be delivered by a respiratory physician (interventional pulmonologist) in a tertiary teaching hospital during a bronchoscopic procedure. The bronchoscopy will be delivered during general anesthesia. It is anticipated that the bronchoscopic procedure will last less than 60 minutes in total. Treatment will be deemed to have been delivered following the successful treatment during the two bronchoscopies.

Subjects will be required to submit tests during the study including three CT scans (lung), respiratory function tests, exercise testing.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: December 30, 2024
• Est. primary completion date: January 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Subject is diagnosed with chronic bronchitis for a minimum of two years, where chronic bronchitis is defined clinically as chronic productive cough for three months in each of two successive years in a patient in whom other causes of productive cough have been excluded.

2. Subject responds to the first two questions of the CAT must sum to at least 7 points. If the sum of the first two CAT questions is 6 points and the subject's total CAT score is greater than 20 points, the subject may be enrolled.

3. Subject has preprocedure post-bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within three months of enrollment.

4. Subject has had 1 or more COPD exacerbations, defined as an acute worsening in respiratory symptoms that requires additional treatment, in the 12-months prior to enrollment.

5. Subject has a SGRQ score of greater than or equal to 25 and CAT score of greater than or equal to 10.

6. Subject has a cigarette smoking history of at least ten packs years.

7. Subject in the opinion of the site investigator is able to adhere to and undergo two bronchoscopies and has provided a signed informed consent.

Exclusion Criteria:

1. Subject has lower respiratory infection (e.g., common cold, pneumonia, MAI, tuberculosis) within the six weeks prior to the initial treatment bronchoscopy or mild or moderate COPD exacerbation (per GOLD guidelines) within 4 weeks of the procedure.

2. Subject is taking > 10 mg of prednisolone or prednisone per day.

3. Subject has an implantable cardioverter defibrillator or pacemaker.

4. Subject has a history of cardiac arrhythmia within past two years.

5. Subject has history of unresolved lung cancer in last 5 years.

6. Subject has bullous disease as defined by bullae exceeding 3 cm in diameter on HRCT.

7. Subject has pulmonary nodule or cavity rthat in the judgement of the investigator may require intervention during the course of the study.

8. Subject has prior lung surgery, such as lung transplant, LVRS, lung implant/prosthesis, metal stent, valves, coils, bullectomy, segmentectomy, or lobectomy. Pneumothorax without lung resection is acceptable. Pleural procedures without surgery are acceptable.

9. Subject has clinically significant cardiomyopathy.

10. Subject has severe bronchiectasis as outlined in the report of the CT scan of the chest by the interpreting radiologist or in the view of the PI, those findings bronchiectasis or any other significant second lung disease, are the main drivers of the patient's clinical symptoms.

11. Subject actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 6 months.

12. Subject has the inability to walk over 100 meters in 6 minutes.

13. Subject has clinically significant serious medical conditions, such as: congestive heart failure, angina or myocardial infarction in the past year, renal failure, liver disease cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension or autoimmune disease.

14. Subject has uncontrolled GERD.

15. Subject has sever pulmonary hypertension.

16. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).

17. Subject is pregnant, nursing, or planning to get pregnant during study duration.

18. Subject has received chemotherapy within the past 6 months or is expected to receive chemotherapy during participation in this study.

19. Subject is or has been in another clinical investigational study within 6 weeks of baseline.

20. Subject on anticoagulation for cardiovascular indications and is unable to have anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for at least seven days prior to bronchoscopy in the opinion of the Investigator.

Related Conditions & MeSH terms

• Acute Disease
• Bronchitis
• Bronchitis, Chronic
• Chronic Bronchitis
• Copd Bronchitis

Intervention

Device:
• RheOx
RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Locations

Country	Name	City	State
United States	MedStar Health	Baltimore	Maryland
United States	University of Alabama Lung Health Center	Birmingham	Alabama
United States	Beth Israel Deaconess	Boston	Massachusetts
United States	University of Chicago	Chicago	Illinois
United States	University of Iowa	Iowa City	Iowa
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	Temple University School of Medicine	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Gala Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Hospitalization Rate	The rate of hospitalizations (events/pt/year)	12 months
Primary	Safety Through 12 Months: Rate of Serious Adverse Events	Rate of serious adverse events of interest through 12 months. Events of interest are death, COPD exacerbation requiring hospitalization, pneumothrax within 2 days of procedure, pneumonia within 7 days of procedure, respiratory failure or arrhythmia requiring intervention.	12 months
Secondary	Clinical Utility: SGRQ Score at 6 Months	The change from baseline to 6 months in St. George's Respiratory Questionnaire (SGRQ) total score.	6 months
Secondary	Clinical Utility: SGRQ Score at 12 Months	The change from baseline to12 months in St. George's Respiratory Questionnaire (SGRQ) total score	12 months
Secondary	Clinical Utility: CAT Total Score at 6 Months	The change from baseline to 6 months in COPD Assessment Test (CAT) total score	6 months
Secondary	Clinical Utility: CAT Total Score at 12 Months	The change from baseline to 12 months in COPD Assessment Test (CAT) total score	12 months